Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Roopa DeChowdhury"'
Autor:
Cynthia Helsabeck, Seth M. Steinberg, Takefumi Komiya, William D. Figg, Guinevere Chun, Marc S. Ballas, Wendy B. Bernstein, Roopa DeChowdhury, Jaclyn LoPiccolo, Joell J. Gills, Hyejeong Root, Shigeru Kawabata, Gideon M. Blumenthal, Phillip A. Dennis, Betsy Morrow, Erin R. Gardner
Publikováno v:
Oncotarget
Nelfinavir is an HIV protease inhibitor being repurposed as an anti-cancer agent in preclinical models and in small oncology trials, yet the MTD of nelfinavir has not been determined. Therefore, we conducted a Phase Ia study to establish the maximum
Autor:
Gideon M. Blumenthal, Susan Fioravanti, Marc S. Ballas, Stephen A. Wank, John C. Morris, Roopa DeChowdhury, Stephen M. Hewitt, Phillip A. Dennis, Betsy Morrow, Arun Rajan, Takefumi Komiya, Thomas J. Hornyak, Regan M. Memmott
Publikováno v:
The Oncologist
Lessons Learned This is the first human interventional study in patients with Cowden syndrome that is driven by inactivation of germline PTEN gene. Single-agent sirolimus, a mTOR inhibitor, suppressed mTOR signaling in surrogate human tissues without
Autor:
James J. Driscoll, Roopa DeChowdhury
Publikováno v:
Targeted oncology. 5(4)
The ubiquitin (Ub)+proteasome proteolytic pathway is responsible for the selective degradation of the majority of nuclear and cytosolic proteins. The proteasome is a high molecular weight multicatalytic protease that serves as the catalytic core of t
Autor:
Betsy Morrow, Regan M. Memmott, Stephen M. Hewitt, Douglas H. Weinstein, Michell Manu, Phillip A. Dennis, Gideon M. Blumenthal, Marc S. Ballas, Stephen A. Wank, Jennifer Morris, Roopa Dechowdhury, Thomas J. Hornyak, Takefumi Komiya, Suzanne Fioravanti
Publikováno v:
Journal of Clinical Oncology. 31:2532-2532
2532 Background: CS is characterized by germline PTEN mutations. Because tumors from CS patients show increased activation of the PI3K/Akt/mTOR pathway, mTOR inhibitor such as S might have activity in such patients. Methods: Eligibility: subjects wit